

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 April 2024 (04.04.2024)



(10) International Publication Number
WO 2024/073595 A2

(51) International Patent Classification:
Not classified

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2023/075413

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
28 September 2023 (28.09.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/410,857 28 September 2022 (28.09.2022) US

(71) Applicant: ATALANTA THERAPEUTICS, INC.
[US/US]; 51 Sleeper Street, 7th Floor, Boston, MA 02210
(US).

(72) Inventors: HASSLER, Matthew; 126 Border St, Apt 512,
Boston, MA 02128 (US). CURTIS, Daniel; 57 Brettwood
Rd, Belmont, MA 02478 (US). DA CRUZ GODINHO,
Bruno, Miguel; 4 Fielding Rd, Reading, MA 01867 (US).
KINBERGER, Garth, A.; 29 Manila Ave, Hyde Park, MA
02136 (US).

(74) Agent: QUARTARARO, Justin, S. et al.; Clark & Elbing
LLP, 101 Federal Street, 15th Floor, Boston, MA 02110
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMPOSITIONS AND METHODS FOR TREATMENT OF HUNTINGTON'S DISEASE

(57) Abstract: The present disclosure provides single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a Hunt-
ington (*HTT*) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside link-
age modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such
as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5' phosphorus
stabilizing moiety and/or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of
the disclosure to the central nervous system of a subject, such as a subject identified as having Huntington's Disease.



WO 2024/073595 A2